CDC20 and breast carcinoma: Others have shown that overexpression of CDC20 indicates unfavorable prognosis and poor response to endocrine therapy in ER + breast cancer (Alfarsi et al., 2019; Tang et al., 2019); in contrast, we discovered that CDC20 was related to worse prognosis only in the TNBC subtype, and we think that the different datasets that we analyzed result in the inconsistency.